Keck Medicine physicians become first to implant epilepsy-controlling device

December 19, 2013
University of Southern California neurosurgeon Charles Liu, M.D., Ph.D., is professor of neurological surgery and neurology at the Keck School of Medicine of USC, surgical director of the USC Comprehensive Epilepsy Program and director of the USC Center for Neurorestoration. Credit: USC/Don Milici

On Dec. 18, Keck Medicine of USC became the world's first medical center to implant a responsive brain device newly approved by the Food and Drug Administration (FDA) to treat epilepsy, with potential to help millions of people worldwide.

The treatment involves surgical implantation of a device that detects and then directly responds to abnormal brain activity to prevent before they occur. In a three-hour surgery, USC faculty physicians implanted the device in a 28-year-old Lakewood, Calif., woman who was diagnosed with in 2004.

"I'm just so lucky to be here at USC," said Kathleen Rivas, an aspiring journalist who sought care from the university's student health center in 2009 while earning her master's degree. "Without faith and trust in my neurologist and neurosurgeon, I don't know where I'd be. My life is in their hands."

Rivas elected to have the implant because medication had not fully controlled her seizures. Over the next few months, her doctors will program the device to detect specific brain activity indicative of a seizure's onset.

The device is the world's only responsive neurostimulation (RNS) system approved for clinical use. USC physicians have been studying the technology since 2006 and are among the first authorized to prescribe its use since FDA approval on Nov. 14.

"This has the potential to be a game-changer in the care of patients with epilepsy," said neurologist Christianne Heck, M.D., M.M.M., associate professor of neurology at the Keck School of Medicine of USC, medical director of the USC Comprehensive Epilepsy Program and principal investigator of the device's clinical study at USC. "Every individual's epilepsy is different. Unlike other neurostimulators on the market, this system looks for just the right circumstances to stop a person's seizure from happening."

Epilepsy is a debilitating neurological condition that causes recurrent seizures, affecting approximately 65 million people worldwide including nearly 3 million in the United States. Those who can tolerate medication and whose seizures are completely controlled usually lead a normal life, but the disease can be devastating for the up to 40 percent who experience uncontrolled seizures.

Most people with epilepsy gain complete control of their seizures or are able to significantly reduce the number of seizures they experience by taking medicine or having surgery to remove the area of the brain where the seizures originate. Having developed new methods to identify and cut out the seizure-onset zone, the surgical epilepsy program at USC has had an 80 percent cure rate among patients who do not respond to anti-seizure medications. RNS may help the remaining 20 percent.

"We have become very good at finding and surgically removing the areas of the brain where these seizures start, but we have limited options when a person's seizures begin in critical zones, such as those that affect speech or movement," said neurosurgeon Charles Liu, M.D., Ph.D., professor of neurosurgery and neurology at the Keck School of Medicine of USC, surgical director of the USC Comprehensive Epilepsy Program and director of the new USC Center for Neurorestoration. "Devices like this provide an option for the population with epilepsy who live with uncontrollable seizures because no available treatment works for them. Implanting it is probably safer than traditional epilepsy surgery, because we're not taking anything out."

Heck, who is also co-director of the USC Center for Neurorestoration, sought to join the clinical trial of the RNS device in December 2005 and testified before the FDA in 2012. USC implanted its first RNS patient in December 2006 and ultimately enrolled and treated 10 patients.

FDA approval of the RNS device came after a randomized clinical trial of 191 patients with drug-resistant epilepsy across 32 clinical sites. The study showed that, by three months after the device was turned on, patients experienced a nearly 38 percent reduction in monthly seizures, compared to a roughly 17 percent reduction in monthly seizures among patients who had the implant turned off. Two years post implant, 55 percent of patients experienced a 50 percent or greater reduction in seizures.

Patients with the RNS device cannot undergo magnetic resonance imaging procedures, diathermy procedures, electroconvulsive therapy or transcranial magnetic stimulation. The energy created from these procedures can be sent through the device and cause permanent brain damage. The most frequent adverse events reported were implant site infection and premature battery depletion.

The USC Center for Neurorestoration

The work that Liu and Heck committed to building USC's Level 4 epilepsy program over the last three years has laid the foundation to establish the Center for Neurorestoration.

"Thanks to Dr. Heck and Dr. Liu's innovation and perseverance, Keck Medicine of USC has a Level 4 epilepsy center, the highest level of medical and surgical evaluation and treatment available for patients with complex epilepsy," said Scott Evans, Pharm.D., M.H.A., CEO of Keck Hospital of USC and USC Norris Cancer Hospital. "The addition of this groundbreaking therapy to our arsenal is testament to our team's dedication to improving the quality of patients' lives."

The center proposes to physically test innovative neural engineering and basic neuroscience to restore neurological circuitry and function in the human brain. The nascent center has already engaged in clinical research partnerships with the USC Viterbi School of Engineering, California Institute of Technology and Rancho Los Amigos National Rehabilitation Center.

"Our faculty physicians and scientists are constantly striving to discover new solutions to the most complex diseases, conditions and disorders," said Carmen A. Puliafito, M.D., MBA, dean of the Keck School of Medicine of USC. "The USC Center for Neurorestoration is a prime example of that pioneering approach—proposing a fundamental departure from current best practices in neurorehabilitation and bridging the gap between science and medicine."

One of the center's current projects includes improving upon the RNS system by testing different levels of electrical stimulation on brain samples in the lab to determine the most effective level for seizure prevention.

"Academic medical centers are centers of innovation and education that directly contribute to the medical breakthroughs that redefine health care," said Tom Jackiewicz, M.P.H., senior vice president and CEO of USC Health. "Dr. Charles Liu and Dr. Christi Heck are blazing a trail in neurological research and care that ultimately will change people's lives for the better. Keck Medicine of USC is proud to serve as a keystone for their efforts."

Explore further: Implantable medical device for epilepsy

Related Stories

Implantable medical device for epilepsy

December 3, 2013
(Medical Xpress)—Physicians at the University of Rochester Medical Center (URMC) Strong Epilepsy Center were involved in the recent approval of a new treatment for epilepsy. The implantable medical device – called the ...

FDA approves implanted brain stimulator for epilepsy

November 14, 2013
(HealthDay)—The U.S. Food and Drug Administration on Thursday gave its approval to a new implanted device that lowers the rate of seizures among people with epilepsy.

Brain stimulator shown to reduce 'untreatable' epileptic seizures

November 8, 2011
Brain stimulation, already approved by the U.S. Food and Drug Administration for the treatment of Parkinson's disease and essential tremor, has now been shown to offer significant relief to patients with intractable seizures ...

FDA panel backs brain stimulator for epilepsy

February 25, 2013
(HealthDay News) - A U.S. Food and Drug Administration panel has unanimously backed a device that lowers the rate of seizures among people with epilepsy.

FDA panel to consider brain stimulator for epilepsy

February 21, 2013
(HealthDay News) - A U.S. Food and Drug Administration advisory panel will weigh on Friday the merits of a new therapy for some people with epilepsy who have seizures that don't respond to medication.

World-first study predicts epilepsy seizures in humans

May 2, 2013
A small device implanted in the brain has accurately predicted epilepsy seizures in humans in a world-first study led by Professor Mark Cook, Chair of Medicine at the University of Melbourne and Director of Neurology at St ...

Recommended for you

Hunger-controlling brain cells may offer path for new obesity drugs

July 28, 2017
Is the solution to the obesity epidemic all in our heads? A study by researchers at The Rockefeller University suggests that it might be.

Faster-acting antidepressants may finally be within reach

July 28, 2017
Some activity patterns in the brain can be dangerous, producing persistent dark moods that drain people's motivation, pleasure, and hope. For the past thirty years, pills like Prozac or Zoloft—collectively known as selective ...

New surgical strategy offers hope for repairing spinal injuries

July 28, 2017
Scientists in the UK and Sweden previously developed a new surgical technique to reconnect sensory neurons to the spinal cord after traumatic spinal injuries. Now, they have gained new insight into how the technique works ...

In witnessing the brain's 'aha!' moment, scientists shed light on biology of consciousness

July 27, 2017
Columbia scientists have identified the brain's 'aha!' moment—that flash in time when you suddenly become aware of information, such as knowing the answer to a difficult question. Today's findings in humans, combined with ...

Scientists block evolution's molecular nerve pruning in rodents

July 27, 2017
Researchers investigating why some people suffer from motor disabilities report they may have dialed back evolution's clock a few ticks by blocking molecular pruning of sophisticated brain-to-limb nerve connections in maturing ...

Social influences can override aggression in male mice, study shows

July 27, 2017
Stanford University School of Medicine investigators have identified a cluster of nerve cells in the male mouse's brain that, when activated, triggers territorial rage in a variety of situations. Activating the same cluster ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.